Skip to main content
MedVellum
QuestionsVideosPricing

MedVellum

Fellowship exam preparation across every specialty: source-verified topics, questions in every format, and videos.

Product

  • Specialties
  • Questions
  • Videos
  • Exam tools
  • Pricing

Verification & policy

  • Verified register
  • Editorial policy
  • Privacy
  • Terms

Account

  • Sign in
  • Create account
  • Dashboard
  • Account & billing

© 2026 MedVellum. For education only — not a substitute for clinical judgement.

llms.txtPsychiatry LLM catalogSitemap

ICU TopicsRenal / RRT

ICU · Renal / RRT

CRRT — Circuit, Prescription, Anticoagulation & Troubleshooting

Also known as Continuous renal replacement therapy · CRRT circuit · CRRT prescription · CRRT anticoagulation · Citrate anticoagulation · Regional citrate · Filtration fraction · Pre-dilution · Post-dilution · CRRT troubleshooting · Circuit clotting · Access pressure · Transmembrane pressure

The CRRT is delivered through a blood circuit — the dual-lumen central access, the blood pump, the pre-dilution (the replacement fluid before the filter), the haemofilter (the hollow-fibre membrane), the post-dilution (the replacement fluid after the filter), the air-trap, and the return. The pressures (the access negative, the return positive, the filter transmembrane) monitor the circuit patency and the clotting. The prescription: the modality (the CVVH, the CVVHDF), the dose (the effluent 20 to 25 mL/kg/h), the blood flow, the fluid balance, the fluid composition, and the anticoagulation. The anticoagulation is the regional citrate (the preferred; the post-filter ionized calcium 0.25 to 0.35 mmol/L; the total-to-ionized ratio under 2.5; the risks the metabolic alkalosis, the acidosis in the liver failure, the hypercalcaemia) or the heparin or none. The troubleshooting: the circuit clotting (the inadequate anticoagulation, the high filtration fraction, the low blood flow), the high access pressure (the catheter kink or the position), the air-in-line, and the electrolyte and the nutrient loss (replace the K, the phosphate, the Mg, the increased nutrition).

high44 referencesUpdated 1 Sept 202636 min readSource-verified · Sept 2026

Checked against its sources on 2 Sept 2026

Practise this topic

  • 8 MCQs

Your progress

Saved on this device.

Practise this topic8 MCQs with explanations

Target exams

CICMFFICMEDIC
On this page
Study tools

Your progress

Saved on this device.

Practise this topic8 MCQs with explanations

Target exams

CICMFFICMEDIC

Overview — the four questions of every circuit

A CRRT circuit is plumbing, and your job is to keep it patent and delivering. Four questions run the bedside: is the circuit flowing, is the prescription right, is the anticoagulation holding, and why did it clot. Answer those four and you hold the whole topic.[16]

Continuous renal replacement therapy runs at the bedside around the clock, clearing solute and water slowly enough to keep the haemodynamics stable. The price of that gentleness is a circuit that clots — and the craft is keeping it running.[16]

ICU Fellowship (CICM) Pro

Continue reading

You have read the opening of this topic. The complete unit — every section and its primary-source references — is part of the ICU Fellowship (CICM) fellowship library.

Sign in to continueSee pricing
References44ShowHide
  1. [1]Hetzel GR, Schmitz M, Wissing H, et al. Regional citrate versus systemic heparin for anticoagulation in critically ill patients on continuous venovenous haemofiltration: a prospective randomized multicentre trial Nephrol Dial Transplant, 2011.PMID 20876598
  2. [2]Monchi M, Berghmans D, Ledoux D, et al Citrate vs. heparin for anticoagulation in continuous venovenous hemofiltration: a prospective randomized study Intensive Care Med, 2004.PMID 14600809
  3. [3]Tsujimoto H, Tsujimoto Y, Nakata Y, et al Pharmacological interventions for preventing clotting of extracorporeal circuits during continuous renal replacement therapy Cochrane Database Syst Rev, 2020.PMID 32164041
  4. [4]Oudemans-van Straaten HM Citrate anticoagulation for continuous venovenous hemofiltration Crit Care Med, 2009.PMID 19114912
  5. [5]Legrand M, Tolwani A Anticoagulation strategies in continuous renal replacement therapy Semin Dial, 2021.PMID 33684244
  6. [6]Bianchi NA, Altarelli M, Schneider AG Complications of Regional Citrate Anticoagulation for Continuous Renal Replacement Therapy: An Observational Study Blood Purif, 2020.PMID 32126564
  7. [7]Lameire N, Kellum JA Contrast-induced acute kidney injury and renal support for acute kidney injury: a KDIGO summary (Part 2) Crit Care, 2013.PMID 23394215
  8. [8]Wald R, Beaubien-Souligny W, Chanchlani R, et al. Delivering optimal renal replacement therapy to critically ill patients with acute kidney injury Intensive Care Med, 2022.PMID 36066597
  9. [9]Warkentin TE Fondaparinux for Treatment of Heparin-Induced Thrombocytopenia: Too Good to Be True? J Am Coll Cardiol, 2017.PMID 29169471
  10. [10]Zhang W, Chen X, Chen Y, et al. Clinical experience with nadroparin in patients undergoing dialysis for renal impairment Hemodial Int, 2011.PMID 21722301
  11. [11]Arcangeli A, Rocca B, Salvatori G, et al. Heparin versus prostacyclin in continuous hemodiafiltration for acute renal failure: effects on platelet function in the systemic circulation and across the filter Thromb Res, 2010.PMID 20185164
  12. [12]Kozek-Langenecker SA, Spiss CK, Gamsjäger T, et al. Anticoagulation with prostaglandins and unfractionated heparin during continuous venovenous haemofiltration: a randomized controlled trial Wien Klin Wochenschr, 2002.PMID 12060975
  13. [13]Langenecker SA, Felfernig M, Werba A, et al Anticoagulation with prostacyclin and heparin during continuous venovenous hemofiltration Crit Care Med, 1994.PMID 7956281
  14. [14]Wang W, Zhao J, Zhang X, et al. Comparison of Anticoagulant Effects of Nafamostat Mesilate and Heparin in Continuous Renal Replacement Therapy for Patients with High Bleeding Risk: A Meta-Analysis Systemic Review Kidney Dis (Basel), 2026.PMID 41909499
  15. [15]Chen Y, Feng F, Li Q, et al. Safety and effectiveness of nafamostat mesylate in continuous renal replacement therapy in patients with sepsis-associated acute kidney injury: a prospective randomized controlled trial Open Med (Wars), 2026.PMID 41737413
  16. [16]Dai T, Shah A, Chong CC, et al. Evolution of continuous renal replacement therapy scenarios and the rise of anticoagulant-free continuous veno-venous hemodiafiltration Curr Opin Nephrol Hypertens, 2026.PMID 41263052
  17. [17]Rhee H, Berenger B, Mehta RL, et al. Regional Citrate Anticoagulation for Continuous Kidney Replacement Therapy With Calcium-Containing Solutions: A Cohort Study Am J Kidney Dis, 2021.PMID 33798636
  18. [18]Vinsonneau C, Allain-Launay E, Blayau C, et al. Renal replacement therapy in adult and pediatric intensive care : Recommendations by an expert panel from the French Intensive Care Society (SRLF) with the French Society of Anesthesia Intensive Care (SFAR) French Group for Pediatric Intensive Care Emergencies (GFRUP) the French Dialysis Society (SFD) Ann Intensive Care, 2015.PMID 26714808
  19. [19]Fabbri LP, Nucera M, Becchi P, et al Regional anticoagulation and antiaggregation for CVVH in critically ill patients: a prospective, randomized, controlled pilot study Acta Anaesthesiol Scand, 2010.PMID 19650808
  20. [20]Bellomo R, Cass A, Cole L, Finfer S, et al. Intensity of continuous renal-replacement therapy in critically ill patients N Engl J Med, 2009.PMID 19846848
  21. [21]Palevsky PM, Zhang JH, O'Connor TZ, Chertow GM, et al. Intensity of renal support in critically ill patients with acute kidney injury N Engl J Med, 2008.PMID 18492867
  22. [22]Oudemans-van Straaten HM, Ostermann M Citrate anticoagulation for CRRT: don't always trust the postfilter iCa results! Crit Care, 2015.PMID 26635277
  23. [23]Assefi M, Leurent A, Blanchard F, Quemeneur C, et al. Impact of increasing post-filter ionized calcium target on filter lifespan in renal replacement therapy with regional citrate anticoagulation: A before-and-after study J Crit Care, 2023.PMID 37379797
  24. [24]Assefi M, Braik R, James A, Clavieras N, et al. Impact of increasing post-filter ionised calcium target on regional citrate anticoagulation efficacy in ICU continuous renal replacement therapy: the non-inferiority randomised controlled Ca-CIBLE protocol BMJ Open, 2024.PMID 39327056
  25. [25]Schultheiß C, Saugel B, Phillip V, Thies P, et al. Continuous venovenous hemodialysis with regional citrate anticoagulation in patients with liver failure: a prospective observational study Crit Care, 2012.PMID 22913794
  26. [26]Zhang W, Bai M, Yu Y, Li L, et al. Safety and efficacy of regional citrate anticoagulation for continuous renal replacement therapy in liver failure patients: a systematic review and meta-analysis Crit Care, 2019.PMID 30678706
  27. [27]Wang F, Lin L, Li P, Huang X, et al. Saline flushing to prevent circuit clotting during CRRT without anticoagulant: a randomized controlled study BMC Nurs, 2025.PMID 40855484
  28. [28]Cuker A, Gimotty PA, Crowther MA, Warkentin TE, et al. Predictive value of the 4Ts scoring system for heparin-induced thrombocytopenia: a systematic review and meta-analysis Blood, 2012.PMID 22990018
  29. [29]Ampatzidou F, Argyriadou E, Amaniti C, Sarridou D, et al. Postoperative Thrombocytopenia in Cardiac Surgery: Patterns, Differential Diagnosis and Management of Heparin-Induced Thrombocytopenia J Clin Med, 2025.PMID 41464670
  30. [30]Capuano I, Riccio E, Buonanno P, Tufano A, et al. Heparin-induced thrombocytopenia: a challenging diagnosis in haemodialysis-state of art and review of the literature Clin Kidney J, 2026.PMID 42111239
  31. [31]Lewis BE, Wallis DE, Berkowitz SD, Matthai WH, et al. Argatroban anticoagulant therapy in patients with heparin-induced thrombocytopenia Circulation, 2001.PMID 11294800
  32. [32]Sinatra N, Cuttone G, Geraci G, Carollo C, et al. Correlation Between Hypophosphatemia and Hyperventilation in Critically Ill Patients: Causes, Clinical Manifestations, and Management Strategies Biomedicines, 2025.PMID 41153669
  33. [33]Li P, Li M, Yin W, Zhou Z, et al. Efficacy and safety of regional citrate anticoagulation using calcium-containing replacement solution in different modalities of continuous renal replacement therapy: a randomized controlled trial BMC Nephrol, 2025.PMID 41199170
  34. [34]Dimski T, Brandenburger T, Vollmer C, Kindgen-Milles D, et al. A safe and effective protocol for postdilution hemofiltration with regional citrate anticoagulation BMC Nephrol, 2024.PMID 38982339
  35. [35]Toprak HB, Taşkın G, Bayrak MA, Sallan M, et al. Real-World Safety and Circuit Outcomes of Protocolized Divided-Dose Enoxaparin During Continuous Renal Replacement Therapy Without Routine Anti-Xa Monitoring: A Single-Center Competing-Risk Cohort Study J Clin Med, 2026.PMID 42513259
  36. [36]Rhee H, Jung KS, Ku EY Effect of targeted versus fixed dosing of nafamostat mesylate on filter life in patients undergoing continuous renal replacement therapy Sci Rep, 2026.PMID 42477433
  37. [37]Zeng X, Cai X, Liao Z, Xiao Y, et al. Effect of nafamostat mesylate anticoagulation and regional citrate anticoagulation during continuous renal replacement therapy in critically ill patients: a retrospective study of efficacy and safety Ren Fail, 2025.PMID 41188191
  38. [38]Boer W, Verbrugghe W, Hoste E, Jacobs R, et al. Unapparent systemic effects of regional anticoagulation with citrate in continuous renal replacement therapy: a narrative review Ann Intensive Care, 2023.PMID 36899104
  39. [39]Yessayan L, Tolwani A, Heung M, Szamosfalvi B, et al. Troubleshooting Ionized Hypocalcemia in Patients on Continuous KRT with Regional Citrate Anticoagulation Kidney360, 2026.PMID 41201866
  40. [40]Parienti JJ, Mongardon N, Mégarbane B, Mira JP, et al. Intravascular Complications of Central Venous Catheterization by Insertion Site N Engl J Med, 2015.PMID 26398070
  41. [41]Yadava D, Tripathi M, Rai S, Malviya D, et al. A study of citrate and bivalirudin for anticoagulation during continuous renal replacement therapy in critically ill patients with acute kidney injury Saudi J Anaesth, 2026.PMID 41710639
  42. [42]Forsal I, Pouchoulin D, Roos V, Echeverri J, et al. Net buffer load during regional citrate anticoagulated continuous renal replacement therapy PLoS One, 2025.PMID 39883646
  43. [43]Hu C, Shui P, Zhang B, Xu X, et al. How to safeguard the continuous renal replacement therapy circuit: a narrative review Front Med (Lausanne), 2024.PMID 39234046
  44. [44]Kameda S, Fujii T, Ikeda J, Kageyama A, et al. Unfractionated heparin versus nafamostat mesylate for anticoagulation during continuous kidney replacement therapy: an observational study BMC Nephrol, 2023.PMID 36642717

Test yourself

Practise what you just read

  • 8 MCQs
ICU Fellowship (CICM) Pro

$29/ monthor $279 / year

The complete ICU Fellowship (CICM) library, every exam format, one subscription.

  • Complete library for one chosen specialty
  • Timed MCQ mock exams and spaced review
  • Clinical cases & cross-table vivas
See pricingSign in
PreviousMyasthenia Gravis & Myasthenic Crisis — NMJ Weakness, PLEX/IVIG & Steroid ExacerbationNeurocritical care / neuromuscularNextRenal Replacement Therapy Modalities — IHD vs CVVH vs CVVHDF vs SLEDRenal / RRT